Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

UroGen Pharma, IntraGel Therapeutics collaborate on biodegradable SRGel platform and oncology pipeline expansion, $7M equity investment
Licensing deal, oncology, drug delivery, small molecule, equity investment - Read more

Alvotech, Lotus Pharmaceutical partner on biosimilars to durvalumab and emicizumab, up to $150M deal
Licensing deal, oncology, rare disease, biosimilar, milestone payments, commercialization - Read more

Charles River Laboratories, Medigen Vaccine Biologics Corp collaborate on next-generation multivalent enterovirus vaccine using NGS
Research collaboration, vaccine, infectious disease, NGS, CMC - Read more

Ready to supercharge your marketing AND sales workflows into biopharma?

You won’t want to miss this webinar, where Kimo (Hapatune) and Anis (Science 2 Sales) get into the nitty-gritty of both:

• Audience segmentation (how tailored marketing content can more effectively engage a focused bioprocess customer segment) and
• Cold calling (the technical underpinning and strategies + mindset to win at it)

Join us August 26th - register for free here!

NurExone Biologic closes C$1.07M ($775K) private placement for general working capital purposes
Exosome therapy, neurological, regenerative medicine, preclinical - Read more

Gossamer Bio plans up to $250M private placement, funding seralutinib toward potential FDA approval
Clinical-stage, pulmonary arterial hypertension, small molecule, cardiovascular - Read more

Astromech raises $20M, expanding AI-driven computational biology and genomic research teams
AI/ML platform, computational biology, oncology, longevity, genomics - Read more

PleoPharma receives $6.5M NIDA grant to advance Phase 3 cannabis addiction trial
Clinical-stage, addiction medicine, small molecule, neurological, cannabis - Read more

Roche invests $750M to double Oregon Genentech facility, adding fill-finish manufacturing capacity by 2031
Fill-finish manufacturing, oncology, immunology, neurology, operational, major transaction - Read more

Aurinia Pharmaceuticals settles with Teva Pharmaceuticals, protecting Lupkynis from generics until December 2036
Small molecule, autoimmune, patent litigation, competitive, market exclusivity - Read more

Werewolf Therapeutics, Ambros Therapeutics merge in $150M deal targeting rare CRPS-1 pain disorder
Small molecule, rare disease, major transaction, strategic - Read more

FDA publishes 55 product-specific guidances to accelerate generic drug development and ANDA approvals
Generic drugs, oncology, regulatory, operational - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Boehringer Ingelheim places Ph1 trial of (BI 3031185) on voluntary hold following safety event
Small molecule, neurological, oral drug, borderline personality disorder, ADHD - Read more

FDA urged by lawmakers to reject China clinical data after three gene therapy trial deaths
Gene therapy, rare disease, regulatory, patient safety - Read more

FDA issues Complete Response Letter to Xspray Pharma for Dasynoc (dasatinib) targeting chronic myeloid leukemia and acute lymphoblastic leukemia
Small molecule, cancer, dasatinib, chronic myeloid leukemia, acute lymphoblastic leukemia, manufacturing - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here